This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Tipapkinogene sovacivec
DrugBank Accession Number
DB06239
Background

Not Available

Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Recombinant
Synonyms
  • DNA (synthetic vaccinia virus strain MVA human papillomavirus-targeted)
  • MVA-HPV-IL2 vaccine
  • Tipapkinogene sovacivec
External IDs
  • R-3484
  • RG 3484
  • RO5217790
  • TG 4001
  • TG-4001
  • TG4001

Pharmacology

Indication

Investigated for use/treatment in cervical dysplasia/cancer, viral infection, and vulvar dysplasia and carcinoma.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

TG 4001 is based on the modified vaccinia virus Ankara (MVA virus) carrying and expressing HPV16 E6 and E7 genes. The MVA vector is a highly attenuated strain of vaccinia virus that combines an extensive history of safety with the ability to stimulate a strong immune response to antigens. The TG 4001 therapeutic vaccine induces specific immunity by presentation of E6 and E7 antigens to T cells via major histocompatibility complex (MHC) class I and II inducing specific cellular and humoral responses. A second mechanism may be a non-specific activation of the immune system via the vaccinia virus and the interleukin 2 (IL2) adjuvant of the immune response. TG 4001 could have further applications beyond Cervical Intraepithelial Neoplasia (CIN) 2/3 as a single agent in low grade CIN (CIN1) or cervical cancers in combination with existing treatments. [Transgene press release]

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
P34L5Y2SR5
CAS number
1052105-48-2

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentCervical Intraepithelial Neoplasia (CIN)1
1, 2RecruitingTreatmentHPV-Related Anal Squamous Cell Carcinoma / HPV-Related Carcinoma / HPV-Related Cervical Carcinoma / HPV-Related Penile Squamous Cell Carcinoma / HPV-Related Vulvar Squamous Cell Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Drug created at March 19, 2008 16:18 / Updated at June 12, 2020 16:52